ACXP Acurx Pharmaceuticals, Inc.

Nasdaq www.acurxpharma.com


$ 6.93 $ -0.23 (-3.27 %)    

Friday, 17-Oct-2025 16:43:17 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 6.8
$ 7.02
$ 6.50 x 45
$ 6.85 x 2
$ 6.61 - $ 7.11
$ 3.80 - $ 41.00
74,604
na
10.78M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-17-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-15-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-16-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 acurx-pharma-secures-australian-patent-for-dna-polymerase-iiic-inhibitors-expanding-acx-375c-coverage-across-five-countries

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company de...

 hc-wainwright--co-reiterates-buy-on-acurx-pharmaceuticals-maintains-31-price-target

HC Wainwright & Co. analyst Matthew Keller reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $31 p...

 acurx-pharma-receives-favorable-opinion-from-pdco-of-ema-on-acurxs-pediatric-investigation-plan-for-ibezapolstat-use-in-children-with-c-difficile-infection

The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on Acurx's Pediatric Investigati...

 hc-wainwright--co-maintains-buy-on-acurx-pharmaceuticals-raises-price-target-to-31

HC Wainwright & Co. analyst Matthew Keller maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and raises the price...

 acurx-pharmaceuticals-q2-eps-189-up-from-521-yoy

Acurx Pharmaceuticals (NASDAQ:ACXP) reported Q2 EPS $(1.89) Up from $(5.21) YoY

 acurx-pharmaceuticals-announces-1-for-20-reverse-stock-split-trading-post-split-on-august-5-2025

Acurx's common stock is expected to begin trading on a post-split adjusted basis on August 5, 2025STATEN ISLAND, N.Y., July...

 acurx-pharmaceuticals-files-for-mixed-shelf-of-up-to-50m

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION